A global phase 1 trial is underway for SHR-A1811, a novel antibody-drug conjugate targeting HER2 in advanced solid tumors. The trial, known as HORIZON-X, is part of a broader landscape of research into antibody-drug conjugates, which are being explored for their potential in treating various cancers, including breast, colorectal, and lung cancers. The effectiveness of these treatments, including SHR-A1811, is still being studied, with some outlets reporting promising results in certain types of cancer.